Digital health on the front lines of coronavirus checking, treatment and prevention (updated 2 Mar)

Coronavirus (COVID-19), which originated in Wuhan, China and has spread to at least 40 countries and 80,000 victims, with 2,700 fatalities, has been roiling both financial and healthcare markets. The stock price of payers in the US have been hit hard due to an anticipated uptick in illness, but interestingly, Teladoc has been up quite smartly in the past few days. Teladoc reported that one of eight virtual visits in January was due to flu, which isn’t atypical–but half had not used Teladoc before. Analysts do expect that there’s an opportunity for telehealth and telemedicine providers to attract new users due to what this Editor has dubbed ‘conscious contact’–that if you even feel remotely sick, you’re going to turn to a virtual visit.

COVID-19 is not remotely near a pandemic outside of China. The three hallmarks of a pandemic are cross-seasonal outbreaks (so far only in China), cross-geography (done), and most importantly, attacking the well. The fatalities have been among those with compromised immune systems, not among the young and healthy who do get it. It’s alarming, like SARS, because of the origination in animals, and the ease of person-to-person transmission via travel, as the outbreaks in Iran, South Korea, Italy, and on cruise ships visiting Asia have confirmed. In the US, the CDC is reporting that it is not currently spreading in the community, but is preparing for that scenario including containment, and has been since January.

But beyond the virtual visit, there are other areas where digital health is part of dealing with COVID-19:

  • Preventing the spread to the patient’s family members. Avaya has been working in China since January to provide enterprise customers with home agents to prevent the spread of the virus. For hospitals, they have donated equipment to enable remote consultation services and remote visiting video at the hospitals, including observation of isolation wards. They have provided a case study of their work with the Tongxiang Hospital at the Tongxiang Branch of Zhejiang Province People’s Hospital. (Photo at left courtesy of Avaya.) 
  • Another is remote patient monitoring. Sheba Medical Center in Tel Hashomer, Israel, is using Tyto Care to monitor the 12 Israeli returnees from the Diamond Princess cruise ship, who continue to be in isolation. The patients will perform the tests on themselves, especially respiratory tests. Jerusalem Post 
    • Update 2 Mar: A representative from Sheba, the largest hospital system in the Middle East, was kind enough to contact me with additional information on their RPM program for COVID-19. For patients requiring isolation in that stage of treatment, Sheba has implemented a modular ‘field hospital’ setup, similar to what the Israeli (and US) military use, which can be set up in any open area. This isolation is to protect immunosuppressed patients from disease spread in the main hospitals. Telehealth being used in addition to Tyto are the Vici telemedicine robot and the Datos Health app for home treated patients. This Editor believes that both European and US public health systems are looking at the Sheba and Israeli approach.
  • Robots–actually a telehealth cart–are being tested for patient self-testing, much like Tyto Care’s use at Sheba. Robots could also deliver food (although they could also carry germs) and sweep streets.
  • Other monitoring can be done via symptom checkers (Babylon, K, and others). 98point6 released a coronavirus screening chatbot app as early as January, but what they’ve turned up so far is more cases of the flu. STAT
  • Data analytics can pinpoint outbreaks. The Epic, Athenahealth, and Meditech EHRs have released new guidance, testing orders and screening questions (e.g. around travel and contacts) that will help to identify outbreaks.

Update 28 Feb: This Editor would like to know more about UV disinfection being used versus coronavirus for large spaces such as in hospitals and aircraft. If you have information on technologies such as PurpleSun which have been tested against hospital pathogens also being used against coronavirus, please contact Editor Donna.

Healthcare technologies which weren’t around during the SARS and swine flu epidemics may make a big difference in the spread, treatment and mortality rate of COVID-19. Healthcare Dive, HealthTechMagazine

UPDATE 28 FEB

As a service to our Readers, we are providing the following health service update links:

The UK Department of Health and Social Care and Public Health England has provided the following links to coronavirus guidance (hat tip to DOHSC via LinkedIn):

👩‍⚕️ Health:
🚂 Transport:
👩‍🎓 Education:
👨‍💼 Employers:
🏡 Social care:

US Centers for Disease Control (CDC)

World Health Organization (WHO) main website on coronavirus:https://www.who.int/health-topics/coronavirus

Health Canada’s main page: http://ow.ly/bLtF50yfJb7

Symptom checker K Health gains $48 million Series C (NY/Tel Aviv)

While we’re on the subject of symptom checkers (Babylon Health below), K Health, a competitor in the US HQ’d in NYC, but also based in Tel Aviv, announced today their win of $48 million in a Series C funding round, led by 14W and Mangrove Capital Partners. Lerer Hippeau, Anthem (also a partner), Primary Ventures, and others participated. Their total funding is $97 million since November 2016. The new funding, according to Crunchbase News, will be used to scale the model, expand primary care to mobile devices, and expand to international markets. 

K (as they call themselves) concentrates on three areas. One is an AI-powered symptom checker that uses millions (they state) of anonymized medical records to provide a virtual consult. According to Crunchbase, the medical records came from Israel’s second-largest HMO, Maccabi, over 20 years. The app questions the user based on previous answers. K contrasts it to static protocols, or rules-based symptom checking. The second is to provide a primary care visit via text for $19/visit (or unlimited for $39/year) with free follow-ups over two weeks. The third is mental health, specifically treatment for anxiety and depression, a growing area both online and via mobile. The $29/month fee covers unlimited doctor visits and delivered prescription medication, excepting meds that require blood testing.

The symptom checker is available throughout the US and primary care in 47 states. According to Crunchbase’s interview with CEO Allon Bloch, they recently passed their 3 millionth user and are now available in Spanish. The company has grown in the past year from 80 to 200 people. Originally, the company linked to New York-based providers, but moved away from that to the primary care/text model. Their overall goal is to provide affordable diagnoses that are a lot more accurate than ‘Dr. Google’ and that steer the patient to the right care.

Should Babylon Health be serious about expansion to the US, they will be running up against K Health, as well as competitors such as 98point6. In the hybrid app-and-physical model, there are Carbon Health and One Medical. Also Mobihealthnews 

Babylon Health fires back at critic @DrMurphy11; Dr. Watkins–and Newsnight–return fire (UK)

Last month, this Editor took note of the Twitterstorm around Babylon Health on the issues raised surrounding diagnosis of women’s cardiac symptoms. @DrMurphy11, who has been raising performance issues with the Babylon chatbot for the past three years, ran a test on the app. First using a male patient, then a woman, with identical cardiac symptoms, the app returned two different diagnoses: the man was advised to go to an ED on an emergency basis and given information on a heart attack, the woman to her GP in six hours and given information on a panic attack.

@DrMurphy11 came out earlier this week to BBC Two’s Newsnight’s Emma Barnett on a profile of ‘healthcare juggernaut’ Babylon as Dr. David Watkins, a consultant oncologist. You can see him on YouTube here (at the 1 minute and 3 min. 30 mark). He demonstrates the response of the chatbot, using as the patient an older male smoker with chest pains. The chatbot advises him that he might have either gastritis or ‘sickle cell crisis in chest’–and to go to his GP in 6 hours. What is far more likely than sickle cell with this history is, of course, a heart attack, as a consultant cardiologist, Dr. Amitava Banerjee confirmed on the program. Dr. Banerjee has also been critical of Babylon’s chatbot on cardiac diagnosis and Health Secretary Matt Hancock in his visible advocacy of Babylon in the NHS alone (at 6 min.) According to Dr. Watkins, he has been documenting chatbot problems to the MHRA and the CQC since 2017, and the problems haven’t been fixed.

Timed with the Newsnight piece, Babylon fired back with a press release labeling Dr. Watkins a “troll” and stating that only 100 of his 2,400 tests demonstrated any concerns with the chatbot. According to the release, Babylon’s staff “have attempted to start a positive conversation with this anonymous person. We have invited him in to start a dialogue, to test our AI, and to meet with the senior doctors who build our products” without response. Babylon has also cited that all of Dr. Watkins’ trials were theoretical tests and cites millions of real uses without a single report of harm, that it meets regulatory standards in five countries including use in the NHS, and that its real life users are highly satisfied (85 percent at 5 stars).

At 6:48 to 12:40 in the video, Newsnight’s Emily Maitlis grills both Babylon’s Dr. Keith Grimes and Dr. Watkins. She brings up that Babylon’s former head of regulatory affairs, Hugh Harvey, had stated that no one has assessed how well the app works. Dr. Watkins also counters Babylon’s non-contact claim that he contacted one of the Babylon leadership members back in 2018 on chatbot problems. Dr. Grimes responded to Ms. Maitlis’ remark that founder Ali Parsa is not a doctor that over 600 doctors work for Babylon. This Editor will leave it to Readers to decide what side won, or if it was a draw. Also Mobihealthnews global edition. (For US Readers, Newsnight and Ms. Maitlis conducted the exclusive, disastrous–for Prince Andrew–interview on his relationship with the late Jeffrey Epstein.)

A potpourri of upcoming NYC events

Thursday 27 February, 6-8 pm, WeWork Soho
Behavioral Modification and Big Data: How Digital Health Helps Patients with Medication Adherence

HITLAB, which is a digital health research, teaching, and advisory services organization with the objective to improve healthcare delivery worldwide, is presenting a talk on digital health, eye care, and medication adherence. The featured speaker is Dr. Thomas Wong, an Associate Clinical Professor and Director of New Technologies at SUNY Optometry. Cost is $6.93 including Eventbrite’s take! Event information and tickets here.

Upcoming in HITLAB’s Seminar Series are When Patients Lose Patience: The Healthcare Consumer in 2020 (19 March) and The New Clinical Trial: Medication as a Core Business Strategy to Improved Drug Trials (23 April). Future events and notification signup here

Friday 28 February, 8 am to 6.30 pm, CONVENE West 46th Street
Columbia Business School’s 16th Annual Healthcare Conference

Speakers at this CBS conference will focus on the transformative impact New York City is having on the healthcare industry, and are from a cross-section of established healthcare organizations, emerging companies, and investment firms will present informed views. The Conference includes four panels, an inaugural CBS Start-up Showcase, and a Sponsor Expo. It also includes a buffet breakfast and lunch as well as a networking happy hour from 4:30 – 6:30 pm. Cost is $350, $200 for Columbia alumni, and only $75 for students. Conference information and tickets here.

Tuesday-Thursday 12-14 May
Columbia Business School Digital Health Executive Education Course

This three-day intensive executive education course sponsored by Columbia Business School Executive Education and HITLAB is an industry-first program that distills how digital technologies can transform life science research, clinical development, patient experience, operations, and business models. Upon completing the program, participants will earn three days toward a certificate with select alumni and tuition benefits. Application and additional information here.

Tuesday-Thursday 1-3 December, Bryant Park Ballroom
2020 HITLAB Innovators Summit

Mark your calendars for this three-day conference which will focus on the diffusion of digital technologies in the healthcare system, with speakers and attendees who are on the front lines of identifying, validating, integrating, and scaling emerging technologies that are improving patient outcomes. Preliminary conference information and 2019 information here.

Hat tip to HITLAB chair Stan Kachnowski, Ph.D., MPA

‘Unleashing the Digital Premium’ for health in the public sector (UK)

On Tuesday (25 Feb), the Good Governance Institute (GGI) and Legrand Assisted Living & Healthcare unveiled at an event in the House of Lords their report, ‘Unleashing the Digital Premium’. The study, which advocates digital technology to improve services, examines the challenges faced by housing, health and social care in supporting families and communities in enabling healthier independent lives. 

The GGI’s Jessica Lubin previewed the report (available from the Legrand website when you read this on Wednesday 26 February) in her blog. “The digital premium refers to the potential that digital technology has to deliver more cost effective, efficient and reliable services. It does this by preventing issues in the first place, by offering greater flexibility in the delivery of services, and by giving the recipients of these services more independence for longer.” This is contrasted to the current state of, as she terms it, “déjà vu despondency”, from rising demand from a growing aging population and pressure to ‘bend the cost curve’ as is often stated about healthcare costs in the US.

The report proposes that technology and digital services can aid in the delivery of care, and it is largely possible today. It examines the barriers, which are systemic, cultural or regulatory. System integration and cross-department/section/function coordination are absolutely necessary to facilitate better outcomes for these individuals and families. 

This Editor will review the report when available after Wednesday. Release. (Editor’s note: Legrand and Tynetec are long-time advertisers and supporters of TTA)

News roundup: stroke rehab uses Hollywood technology, 3M sues IBM Watson Health on analytics software misuse, AI-based skin cancer detection apps fail, Dictum’s successful telemed use post-pediatric surgery, malware attacks Boston practice network

Motion capture technology being used in stroke and TBI rehab. Best known for turning actors into cartoon superheroes, motion capture tech is now being used at Spaulding Rehabilitation Hospital in Boston for returning mobility to stroke and TBI patients. Attached to the patient are sensors–reflective markers–on key parts of the body. Using an array of infrared cameras, the patient is tracked on gait and other affected motion areas. Doctors and therapists can then better target therapy, plus assistive technologies from orthotics to full exoskeletons. Includes video. STAT

When Giants Sue. 3M is suing IBM Watson Health on their use of licensed 3M software in ‘unauthorized ways’ and charging direct copyright infringement and contract breaches. 3M’s Grouper Plus System analyzes claims and other coded data to help calculate reimbursement. 3M contends that IBM was licensed only for internal use dating back to a Truven agreement in 2007, years before their acquisition by IBM. The suit also adds that IBM then integrated the software into Watson platforms without a license transfer and expansion to cover the use, as well as dodged an audit of the use. The suit is in NY Federal Court. Becker’s Health IT Report

Algorithm-based dermatology apps fail to accurately detect risk for melanomas and similar skin cancer.  A just-published BMJ study determined that these smartphone apps, which use algorithms that catalogue and classify images of lesions into high or low risk for skin cancer and return an immediate risk assessment with subsequent recommendation to the user, are not effective. Six apps were examined, including two with a CE mark. None were FDA-approved and two were cited by the Federal Trade Commission for deceptive marketing. Only one, SkinVision, is still commercially available. Study results do not apply to apps that physicians use in direct telemedicine consults. IEEE Spectrum

Successful test and planned rollout of telemedicine tablet for post-surgery checks at Children’s Hospital of Richmond (Virginia–CHoR). The Dictum Health eVER-HOME tablet used for virtual visits had a 92 percent acceptance rate of telemedicine visits in place of in-person visits, zero return to hospital/ER events, earlier patient discharge post-surgery (12 to 24 hours), and avoidance of long-distance travel by patients for follow-up visits, a significant factor as CHoR is a destination hospital for specialized pediatric surgery. The rollout will include AI capabilities in Dictum’s Care Central platform to help determine rising risk and more. Dictum Health is a company best known for telemedicine units for remote workers (e.g. oil rigs) using their Virtual Exam Room (VER) technologies. Dictum release, mHealth Intelligence

CHoR is having a better week than a physician’s network affiliated with Boston Children’s Hospital. Pediatric Physician’s Organization at Children’s (PPOC) is the victim of a malware attack affecting computer systems at about 500 affiliated physicians and clinicians. The impacted systems have been quarantined and does not affect BCH. Becker’s Hospital Review, Health IT Security  Health IT Security also rounds up other recent data breaches, hacks, and phishing attacks.

Is the bloom off the consumer DNA business? It’s past time for a Genomic Bill of Rights. (updated)

Perhaps a bit of sanity enters. Ancestry, the largest vendor of home-based tests for genetic testing to trace ancestry and seek health information, announced layoffs of 6 percent, or about 100 people, from its Utah and California offices. This follows on post-New Year layoffs at chief rival 23andMe of 14 percent of its staff, also about 100 people.

The slowdown in the consumer appeal of genetic testing is apparently across the board. While one hears of genetic tests being given for holidays and birthdays, there is little repeat need. The market was easily saturated: the early adopters have done their testing; the second wave of consumers which normalize a technology now are increasingly aware of and have privacy concerns about their genetic information being misused. This Editor would add a lingering wave of silly TV and online commercials with wide-eyed folks imagining their connection to ancient royalty or swapping out lederhosen for kilts after their testing report comes back. 

The bright spot for both companies is where they were really heading–healthcare data. AncestryHealth is not being cut back. As previously noted, GSK owns half of 23andme.

This Editor in 2018 advocated a Genomic Bill of Rights where before testing, a genetics testing client would be told how their genomic data is being used and being protected, informed about de-identification, and easily able to opt-out of commercial use. And the revelations about matching to others in the database or health revelations should be done not only with circumspection and respect for the disruption which may happen in the client’s life, but also held to the highest standard of testing. Sometimes that discovery is the equivalent of tossing a hand grenade into a person’s life. There also hasn’t been a lot said about making de-identifiable data identifiable through the ‘nefarious use’ of genomic data sets available through research networks.

DNA is being used for so much advanced medicine and even home testing (example–Cologuard in the US for colon cancer). It’s regrettable that the most public face of genetic testing rests with two companies whose main sell on your past and health has had unintended consequences, and whose main chance lies in the sale of their consumer data. The Verge, CNBC

100% increase in physician telehealth and virtual care usage in three years: AMA study

The American Medical Association’s newest physician survey has a lot of good news for those of us in healthcare tech. It found greater across-the-board physician adoption of digital tools, whether virtual consults, patient visits, adoption of patient portals, workflow enhancements, or clinical decision support.

While current usage was greatest for other tools, the greatest increases were virtual visits via telemedicine, doubling from 14 percent to 28 percent, and remote monitoring for improved care from 13 percent to 22 percent of the over 1,300 physicians surveyed in both years. 

AMA last surveyed physicians on their digital health adoption in 2016. Both the 2019 and 2016 surveys were performed by WebMD and examined seven key digital tools. In current use, 2019/2016:

  1. Remote monitoring for efficiency: 16%/12%
  2. Remote monitoring and management for improved care: 22%/13%
  3. Clinical decision support: 37%/28%
  4. Patient engagement: 33%/26%
  5. Tele-visits/virtual visits: 28%/14%
  6. Point of care/Workflow enhancement: 47%/42%
  7. Consumer access to clinical data: 58%/53%

Also notable was that primary care physicians (PCPs) see greater advantages in digital health more than specialists, though in top two boxes, they are equal. Multi-specialty groups like digital health best.

Providing remote care is also a driver for digital health adoption, the only one which increased several points in the very/somewhat important indicator.

Not surprisingly, older physicians are less enthusiastic about digital health, but they have increased adoption much in line with younger cohorts.

And way back in the appendix of the study, doctors look to emerging technologies to assist them with their chronic care patients, with millenials not that far behind.

Articles: Health Data Management, HealthLeaders
Study: Summary, AMA Digital Health Study 2019

Propel@YH opens again for 2020 accelerator candidates

Yorkshire & Humber AHSN (Academic Health Science Network) today opened applications for the second year of its Propel@YH digital health accelerator. The accelerator is aimed at helping digital health innovators of startup and scale-up size navigate the NHS in the Yorkshire and Humber region and who are already there or are willing to establish an operation there.

10 companies will have access to expert partners such as NHS providers, commissioners and academic institutions. The program this year is being supported by the University of Leeds’ innovation hub, Nexus; Barclays Eagle Labs national incubator network, leading health law firm Hill Dickinson, and Leeds City Council.

Last year, their six finalists were DigiBete, Healthcare Engineering, HeteroGenius, Medicsen, Medicspot and Scaled Insights. 

But hurry–applications close on 12th March. Release, Propel@YH website, application

VA running at least one month late on Cerner implementation launch

Only a week after Veterans Affairs secretary Robert Wilkie reassured the press that the rollout of the Cerner EHR to replace VistA was right on time, FCW was advised by a VA spokesperson that the implementation is only 75-80 percent complete, and more time is needed for the system build and staff training. The 28 March rollout at Spokane, Washington’s Mann-Grandstaff VA Medical Center will have a new ‘go-live’ date according to the spokesperson. Another source said to FCW that the interfaces between Cerner, VA IT, and VistA has been a worse ‘slog’ than anyone imagined, so it made little sense to train anyone on a unfinished system. The date is now estimated to be end of April.

Apparently key Congresscritters on the House Veterans Affairs Committee and IT subcommittees were prepared for the delay by Secretary Wilkie–a wise move–and they applauded the recognition that more preparation and training are required.

VA’s fiscal 2021 budget, revealed on 10 Feb, requested $2.6 billion for the Cerner EHR modernization project, up from $1.5 billion in the prior year. There’s $500 million more for infrastructure readiness and $62 million hike in program management support.

Considering 2019’s digital health investment picture: leveling off may be a Good Thing

2019 proved to be a leveling-off year for digital health investment. The bath may prove to be more cleansing than bubbly.

We noted that the always-fizzy Rock Health engaged in some revisionist history on its forecasts when the final numbers came in–$7.4bn in total investment and 359 deals, a 10 percent drop versus 2018. When we looked back at our 2019 mid-year article on Rock Health’s forecast [TTA 25 July], they projected that the year would end at $8.4 bn and 360 deals versus 2018’s $8.2 bn and 376 deals. That is a full $1bn under forecast and $0.8 below 2018. Ouch!

In their account, the 10 percent dip versus 2018 is due to average deal size–decreasing to $19.8M in 2019–and a drop in late-stage deals. Their analysts attribute this to wobbliness around some high-profile IPOs, citing Uber, Lyft, and Slack, as well as the near-collapse of WeWork right before its IPO towards the end of 2019.

New investors and repeat investors increased to 627 from 585 in 2018, with no real change in composition.

The headliners of 2019 were:

  • Amazon’s acquisition of Health Navigator adding symptom-checking tools to its health offerings
  • Google’s buy of Fitbit
  • Optum’s purchase of Vivify Health, which gives it a full remote patient monitoring (RPM) suite (right when CMS is setting reimbursement codes for RPM in Medicare)
  • Best Buy’s addition of Critical Signal Technologies for RPM
  • Phreesia, Livongo’s and Health Catalyst’s IPOs. For Livongo and Health Catalyst, current share prices are off from their IPOs and shortly after: past $25 for LVGO and $31 for HCAT. Phreesia closed today at a healthy $33, substantially up from PHR’s debut at $15. (Change Healthcare, on the other hand, is up a little from its IPO at $16, which isn’t bad considering their circumstances on their financing.)

Rock Health only counts US deals in excess of $2 million, which excludes the global picture, but includes some questionable (in this Editor’s estimation) ‘digital health’ players like Peloton, explained in the 25 July article.

Rock Health’s analysts close (and justify their revisions) through discussions with VCs expecting further headwinds in the market–then turn around and positively note the Federal backing of further developments in building the foundation for connected health as tailwinds. No bubbly forecasts for 2020–we’ll have to wait.

Is this necessarily bad? This Editor likes an occasional dose of reason and is not displeased at Rock Health’s absence of kvelling.

Confirming the picture is Mercom Capital’s analysis which also recorded a 6 percent dip 2019/2018: $8.9bn with 615 deals, dropping from the $9.5bn and 698 deals in 2018. Their ‘catchment’ is more global than Rock Health, and encompasses consumer-centric and patient-centric technologies and sub-technologies. Total corporate funding reached $10.1bn.

Outcome Health’s Desai reaches settlement with DOJ, SEC

Ashik Desai, the former chief growth officer of point-of-care advertising firm Outcome Health, settled the charges against him brought in Federal court by the Securities and Exchange Commission. The filing was on 4 February. Monetary relief and/or penalties against him will be disclosed at a later date.

Last month, Mr. Desai pleaded guilty to the charges and announced cooperation with the authorities on the criminal charges of securities fraud related to Outcome Health’s capital raises of about $1 bn during 2011 into 2017. Similarly, his former analysts Kathryn Choi and Oliver Han did the same at the end of January.

Remaining are the senior executives who have all entered pleas of  ‘not guilty’: founders Rishi Shah and Shradha Agarwal, both of Chicago, and Brad Purdy, their former COO and CFO, all in their 30s. All of them blame Mr. Desai, who is presently 26 and started at Outcome Health as an intern.  Pass the popcorn for a dramatic tale of complex and multi-layered fraud, likely in the spring. Becker’s Health IT and CIO Report, Chicago Tribune  Also TTA 17 Dec and 3 Dec

Comings and goings, wins and losses: VA’s revolving door spins again, NHS sleep pods for staff, Aetna’s Bertolini booted, Stanford Med takes over Theranos office

VA’s revolving door spins again with #2 person fired, but VistA replacement implementation moves on. James Byrne, deputy secretary, was fired on 3 Feb “due to loss of confidence in Mr. Byrne’s ability to carry out his duties” according to secretary Robert Wilkie. Mr. Byrne, a Naval Academy graduate and former Marine officer, had been VA general counsel, acting deputy secretary starting August 2018, then confirmed five months ago.

Mr. Byrne’s responsibilities included the Cerner implementation replacing VistA and other IT projects (HISTalk), of which Mr. Wilkie stated in a press conference today (5 Feb) “will not impact it at all” (FedScoop). The termination comes in the wake of a House staff member on the House Veterans Affairs committee, herself a Naval Reserve officer, stating that she was sexually assaulted at the VA Medical Center in Washington (NY Times). Axios claims that the White House was disappointed in the way the VA handled the investigation. At today’s presser, Mr. Wilkie denied any connection but attributed the dismissal to ‘not gelling’ with other team members. The launch of Cerner’s EHR is still on track for late March. The turnover at the VA’s top has been stunning: four different secretaries and four more acting secretaries in the last five years. Also CNBC, Military Times.

NHS’ sleep pods for staff to catch a few ZZZZs. A dozen NHS England hospitals are trialing futuristic-looking ‘sleep pods’ for staff to power nap during their long shifts and reduce the possibility of errors and harm by tired clinicians. Most of the locations are in the A&E unit, doctors’ mess, and maternity department. They are available to doctors, nurses, midwives, radiographers, physiotherapists, and medics in training. The pods are made by an American company, MetroNaps, and consist of a bed with a lid which can be lowered along with soothing light and music to aid relaxation. The pods may cost about £5,500 each but are being well-used. Other hospitals are fitting areas out with camp beds and recliner chairs. The sleep breaks take place both during and end of shifts before returning home and average about 17-24 minutes. Everything old is new again, of course–dorm areas were once part of most hospitals some decades back and doctors’ lounges with sofas were popular snooze-gathering areas. Guardian (photo and article)

Mark Bertolini bumped off CVS-Aetna Board of Directors. The former Aetna CEO, who was the engineer of the sale to CVS Health two years ago, isn’t going quietly out the door with his $500 million either. The high-profile long-time healthcare leader told the Wall Street Journal that he was forced off the BOD. He maintains the integration of the Aetna insurance business is incomplete, contradicting CVS’ statement that it’s done. Mr. Bertolini and two other directors are being invited out as CVS-Aetna reduces its board following, it says, best practices in corporate governance. Looking back at our coverage, Mr. Bertolini had hits, bunts (ActiveHealth Management) and quite a few misses (Healthagen, CarePass, iTriage). According to the WSJ, the contentious nature of the statement plus the departure of the company’s president of pharmacy is raising a few eyebrows. And recently, an activist shareholder, Starboard Value LP, has taken a stake in the company. CVS is demonstrating some innovation with rolling out 1,500 HealthHubs in retail locations as MinuteClinics on steroids, so to speak.  Hartford Courant (Aetna’s hometown news outlet) adds a focus on how many jobs will be remaining in the city with a certain skeptical context on CEO Larry Merlo’s promises. 

Stanford taking over Theranos Palo Alto HQ space. HISTalk’s Weekender had this amusing note (scroll down to ‘Watercooler Talk’) that the 116,000-square-foot office building in Stanford Research Park will now house the Stanford medical school. Theranos had been paying over $1 million per month in rent for the facility. The writer dryly notes that Elizabeth Holmes’ bulletproof glass office remains. This Editor humbly suggests the floor-to-ceiling application of industrial-strength bleach wipes and disinfectant, not only in the lab facility but also in that office where her wolf-dog used to mess.

The LA Times reports that Ms. Holmes is also defending herself without counsel in the Phoenix civil class-action lawsuit against Theranos. On 23 January, she dialed in to the court hearing’s audio feed and spoke for herself during that hour. One has to guess that she doesn’t have much to do other than read legal briefs. (Perhaps she sees herself as a cross between Saint Joan and Perry Mason?) Last fall, Ms. Holmes was dropped by Cooley LLP for non-payment of fees [TTA 9 Oct 19]. Williams & Connolly continues to represent her in the criminal DOJ suit, where prison time looms.